Trials / Completed
CompletedNCT00400582
A Pharmacogenomic Study of Candesartan in Heart Failure
Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Montreal Heart Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the impact of genetic variations on the response to candesartan in patients with heart failure who are already treated with an ACE inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Candesartan up to 32 mg daily | Candesartan 4 to 32 mg daily |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2006-11-17
- Last updated
- 2011-07-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00400582. Inclusion in this directory is not an endorsement.